Skip to main content
Clinical Trials/CTRI/2022/01/039544
CTRI/2022/01/039544
Completed
Phase 2

Therapeutic Evaluation of the Efficacy of a Polyherbal Unani Formulation in the form of Habb (Pill) in the Management of Niqris Muzmin (Chronic Gout-Hyperuricemia).

Central Council for Research in Unani Medicine New Delhi0 sites60 target enrollmentTBD

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Health Condition 1: - Health Condition 2: E798- Other disorders of purine and pyrimidine metabolism
Sponsor
Central Council for Research in Unani Medicine New Delhi
Enrollment
60
Status
Completed
Last Updated
3 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
August 22, 2022
Last Updated
3 years ago
Study Type
Interventional

Investigators

Sponsor
Central Council for Research in Unani Medicine New Delhi

Eligibility Criteria

Inclusion Criteria

  • Clinically/Radiologically diagnosed patients of Chronic Gout with Sr. Uric Acid Level \> 7\.2 mg/dL.
  • 1\. Patients with Joint Pain.
  • 2\. Patients with morning stiffness \> 30 minutes.
  • 3\. Patients with joint swelling of the affected joint(s).
  • 4\. Patients with muscular weakness of the joint(s).
  • 5\. Patients with restricted movement of the joint(s).

Exclusion Criteria

  • 1\. Any other disease or syndrome except Niqris.
  • 2\. Pregnant and Lactating women.

Outcomes

Primary Outcomes

Not specified

Similar Trials